| Overview |
| bs-11862R-Cy3 |
| DYX2/KIAA0319 Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DYX2/KIAA0319 |
| 682-760/1072 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Secreted, Cell membrane |
| DLX 2; DLX2; DYLX 2; DYLX2; Dyslexia susceptibility 2; Dyslexia-associated protein KIAA0319 DYX 2; DYX2; K0319_HUMAN; Kiaa0319; MGC176717. |
| DYX2 is a 1072 amino acid single-pass transmembrane protein that contains one MANSC domain and two PKD (Polycystic Kidney Disease) domains, which are usually found in the extracellular regions of proteins and are involved in protein-protein interactions. In DYX2, it is likely that its PKD domains mediate the interaction between neurons and glial fibers during neuronal migration. When overexpressed, this plasma membrane protein colocalizes with EEA1 (early endosome antigen 1) in large intracellular vesicles, suggesting that it is endocytosed and recycled. DYX2 is highly expressed in brain cortex, cerebellum, amygdala, putamen and hippocampus. Defects in the gene encoding DYX2 may be the cause of dyslexia type 2, a relatively common disorder that is characterized by reading performance impairment in the absence of sensory or neurologic disability. There are three isoforms of DYX2 that are produced as a result of alternative splicing events |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz